戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                               Therefore, the nonhepatic action of GlcNAc-TIII promotes hepatocyte pro
2         Zf9 mRNA also is expressed widely in nonhepatic adult rat tissues and the fetal liver.
3 icol acetyltransferase reporter gene in both nonhepatic and hepatic cells.
4 deoxycholic acid, similar rates and types of nonhepatic autoimmune diseases, and/or subsequent develo
5 accumulation metrics; highlights the role of nonhepatic biotransformation; and contributes an in-dept
6 l CT scans were obtained in 80 patients with nonhepatic cancer and no hepatic metastases visible at C
7  recommendations specifically addressing (a) nonhepatic cancer in LT candidates, (b) de novo malignan
8 donor-derived malignancies after LT, and (d) nonhepatic cancer in the pediatric population.
9      Liver transplant in patients with prior nonhepatic cancer is a matter of concern, needing furthe
10 antation in patients with a prior history of nonhepatic cancer.
11 patocellular carcinoma, vascular events, and nonhepatic cancers were not different between vitamin E-
12          The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages.
13 d non-C hepatitis, other liver diseases, and nonhepatic causes as control outcomes.
14 athy, persistent ascites, or death excluding nonhepatic causes of these conditions.
15                                              Nonhepatic causes such as celiac disease, thyroid, and m
16  Mortality attributable to liver disease and nonhepatic causes was also assessed.
17 ty among older recipients was largely due to nonhepatic causes, including infectious, cardiac, and ne
18   T3 regulation of ACCalpha transcription in nonhepatic cell cultures such as chick embryo fibroblast
19 he dedifferentiated cell line HepG2.1 or the nonhepatic cell line HeLa.
20  detected in mouse livers and in hepatic and nonhepatic cell lines overexpressing STAT3/c-Fos/HNF-1.
21 3 in cell lines of hepatic origin but not in nonhepatic cell lines.
22                            Thus, unlike many nonhepatic cell types, rat hepatocytes are resistant to
23     In contrast, the "urea cycle" enzymes in nonhepatic cells are regulated by a wide range of pro- a
24 nduction of the reporter gene in transfected nonhepatic cells but not in liver cells.
25 d receptor alpha, support HBV replication in nonhepatic cells by controlling pregenomic RNA synthesis
26 factor activated by IL-6 in both hepatic and nonhepatic cells efficiently interacts with the SAS.
27                                 In addition, nonhepatic cells have been rendered more efficient at su
28 lular injury is unclear, because findings in nonhepatic cells have implicated autophagy as both a med
29 ithin the nuclear compartment of hepatic and nonhepatic cells in a manner independent of the Arnt pro
30                 Cholesterol elimination from nonhepatic cells involves metabolism to side-chain oxyst
31                          In both hepatic and nonhepatic cells, IL-6 -mediated IGFBP-1 promoter activa
32 and its abnormal expression, particularly in nonhepatic cells, is implicated in the pathogenesis of t
33                                           In nonhepatic cells, lipid synthesis is controlled by stero
34  of apoptotic cell death in both hepatic and nonhepatic cells.
35 ired, it greatly enhances HCV replication in nonhepatic cells.
36 only SAA1 gene but also other liver genes in nonhepatic cells.
37 r signaling pathways leading to apoptosis in nonhepatic cells.
38 ytokine-mediated SAA gene expression in some nonhepatic cells.
39 f advanced liver disease), or too old or had nonhepatic comorbid conditions, substance abuse problems
40  periphery and describes a unique role for a nonhepatic complement source.
41 ession of p450 on apoptosis were observed in nonhepatic COS1 and hepatic HepG2 cells.
42                                   Studies of nonhepatic disease have linked hypotension and cognitive
43 patic decompensation, or another significant nonhepatic disease.
44  after liver surgery or for other hepatic or nonhepatic disorders related to abnormal mPTP opening.
45 th reduced hazard for a range of hepatic and nonhepatic events; (2) an association between SVR and be
46  the mechanism controlling cytokine-induced, nonhepatic expression of the SAA gene.
47 epatic tissues (presumably visceral fat) and nonhepatic fractional spillover (R = 0.81, P < 0.01), co
48 equences on the liver, with little effect on nonhepatic glucose metabolism, whereas insulin delivered
49          These data show that postabsorptive nonhepatic glucose production in humans may contribute t
50                                              Nonhepatic glucose uptake ( micromol.kg(-1).min(-1)) in
51  basal insulin LY2605541 (LY) on hepatic and nonhepatic glucose uptake (non-HGU) was evaluated.
52 ulmonary administration of insulin increases nonhepatic glucose uptake compared with infusion, and sk
53  were greatest in the PoHI and Pe327 groups, nonhepatic glucose uptake increased most in the PeHI gro
54                       Glucose infusion rate, nonhepatic glucose uptake, and tracer-determined glucose
55    Intraportal 5-HT enhances NHGU but blunts nonhepatic glucose uptake, raising the possibility that
56 demonstrate successful lineage conversion of nonhepatic human cells into mature hepatocytes with pote
57 HCV RNAs can replicate in mouse hepatoma and nonhepatic human epithelial cells.
58 of 60 years, the excess mortality was due to nonhepatic, largely age-related problems.
59 3.8% for HDV vs. 24.7% for HBV), followed by nonhepatic malignancies (15.6% vs. 14.8%), cardiac (11.7
60  aware of a heightened potential for certain nonhepatic malignancies among hepatitis B patients, as e
61 line for recurrence-free survival period for nonhepatic malignancies before LTx, based on the type an
62 , mean age 56.9+/-12.8 years) had documented nonhepatic malignancies.
63 he data for patients with a prior history of nonhepatic malignancy and its recurrence post-LTx are li
64                    The rate of recurrence of nonhepatic malignancy was 3% and de novo cancer was 6% i
65 nophen-induced acute liver failure (n = 13), nonhepatic multiple organ failure (n = 28), chronic live
66  VA distribution and kinetics in individual, nonhepatic organs is limited.We examined retinol uptake
67 d.We examined retinol uptake and turnover in nonhepatic organs, including skin, brain, and adipose ti
68                                Cell lines of nonhepatic origin do not independently support HBV repli
69 es with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of no
70 f this study was to examine the patient with nonhepatic pre-LTx malignancies, and their recurrence po
71  study has further confirmed that there is a nonhepatic reservoir for chronic HDV persistence in SjD-
72 al model was developed and demonstrated that nonhepatic splanchnic spillover rates in study A and stu
73 s, assumptions regarding actual spillover in nonhepatic splanchnic tissues were required for the spil
74 significant effect on AAV gene transfer into nonhepatic tissue, indicating that there are distinct ti
75 of [3H]oleate was observed in both liver and nonhepatic tissues (approximately 50% each).
76 ificant correlation between FFA release from nonhepatic tissues (presumably visceral fat) and nonhepa
77  of XAP2 is low in liver compared with other nonhepatic tissues and the AHR exhibits high ligand-indu
78                           On the other hand, nonhepatic tissues are much less sensitive to insulin an
79 ow level of Delta-6 desaturase expression in nonhepatic tissues may need to be reevaluated.
80 the liver and the 5 nonessential proteins in nonhepatic tissues sets up a dichotomy that takes advant
81 ow that bile acids selectively accumulate in nonhepatic tissues under two conditions of impaired live
82 apeutic agent for various diseases affecting nonhepatic tissues, but great caution is required for ve
83 umican, an important mediator of fibrosis in nonhepatic tissues, whereas FABP-1 is paradoxically unde
84 rp) metabolism via the kynurenine pathway in nonhepatic tissues.
85 rp) metabolism via the kynurenine pathway in nonhepatic tissues.
86 nnot act on the liver without also affecting nonhepatic tissues.
87  subtypes that are found in both hepatic and nonhepatic tissues.
88  cell culture lines derived from hepatic and nonhepatic tissues.
89 eriphery produces metabolic abnormalities in nonhepatic tissues.
90 tients with chronic myelogenous leukemia and nonhepatic toxicities between the two groups was not sta
91 gressed, two refused treatment, and five had nonhepatic toxicities).
92 There was however increased odds of grade 3+ nonhepatic toxicity in the high-pulse frequency group (o
93 o enhance their antiviral effects and reduce nonhepatic toxicity.
94                                 The use of a nonhepatic transplant site may avoid intrahepatic compli
95 ntly correlated with AADC expression (n = 15 nonhepatic tumors; maximum standardized uptake value, P